ImmunityBio, Inc.
HealthcareNASDAQ:IBRX · NASDAQ Global Select
-$0.10 today
Vol 8.58M · Avg 17.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
70.3%
avg 36.7%
ROIC
-56.9%
avg -76.4%
ROA
-70.0%
avg -74.8%
Analysis
ROE is currently the strongest return metric at 70.3% versus its period average of 36.7%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard Gerald Adcock | President, Chief Executive Officer & Director | $1.58M | — | 57 | $637,904.00 | 0.06% |
Patrick Soon-Shiong FRCS | Founder, Executive Chairman and Global Chief Scientific & Medical Officer | $1.15M | — | 73 | $0.00 | <0.01% |
David C. Sachs | Chief Financial Officer | $902,174.00 | — | 48 | $320,825.00 | 0.03% |
Regan J. Lauer | Chief Accounting Officer | $522,490.00 | — | 56 | $2.83M | 0.27% |
Enrique Diloné | Chief Technology Officer | — | — | 59 | — | — |
Leonard S. Sender | Chief Medical Officer of Liquid Tumors & Cell Therapy | — | — | — | — | — |
Manju Saxena | Senior Vice President of Product Development & Cell Therapy Program | — | — | — | — | — |
Sandeep K. Reddy | Chief Medical Officer | — | — | — | — | — |
Sarah Singleton | Chief Communications Officer & Head of Patient Advocacy | — | — | — | — | — |
Barry J. Simon | Chief Corporation Affairs Officer & Director | — | — | 61 | $2.83M | 0.27% |
Hans Georg Klingemann | Chief Science Officer of Cellular | — | — | 76 | — | — |
Emily Arison | Senior Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
9
$4.63M
Net Sentiment
$4.63M
Net selling
Most Active
Simon Barry J.
6 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 9 sells worth $4.63M over the last 12 months. That adds up to net selling of $4.63M. Simon Barry J. was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -58.7% | +131.1% (13yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -58.7% over three years. Forward estimates point to Revenue at +131.1% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.47B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
Who manages IBRX?
ImmunityBio, Inc. (IBRX) lists 12 active executives. The top listed executive is Enrique Diloné, Chief Technology Officer.
Are IBRX insiders buying or selling?
Recent insider activity shows net buying of $628.00M.
Explore More
Continue the stock analysis
Jump to another research area for this company.